Studies

  • A randomised, double-blind, placebo controlled trial of the safety and efficacy of topical Alicaforsen enema in active, chronic, antibiotic-refractory primary idiopathic pouchitis.   Inclusion criteria: Active disease ≥6 stools/day OR ≥3 stools above post-IPPA baseline PDAI score ≥7 Endoscopic score ≥2 Chronicity, i.e. symptomatic for......

  • Golimumab dose Optimisation to Adequate Levels to Achieve Response in Colitis GOAL-ARC is a nationwide multi-centred investigator initiated randomized control trial to evaluate the use of personalized Golimumab (GLM) dose adjustment in ulcerative colitis. The primary objective is to ascertain if dose adjustment of GLM, based......

  • IBD Cancer and Serious Infections in Europe     I-CARE is the first observational European prospective cohort study that will provide unique information (safety, efficacy, risk-benefit ratio, and healthcare costs) on the long-term use of recommended therapy in IBD, using a predefined standardized follow-up. These real world data will be used......

  • STEIG is a retrospective study of clinical outcomes of off licence treatment with Ustekinumab for Crohn’s Disease. Ustekinumab (Stelara) is a monoclonal antibody against the common p40 subunit of IL-12 and IL-23. It has been licenced as a treatment for psoriasis for several years and......